-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM Vaccine files NMPA registration for high-potency human diploid rabies vaccine

PUBT·08/24/2026 00:02:30
Listen to the news
AIM Vaccine files NMPA registration for high-potency human diploid rabies vaccine
  • AIM Vaccine submitted a marketing registration application to China’s NMPA for its upgraded high-potency human diploid cell rabies vaccine.
  • Phase III results showed safety, immunogenicity, durability; met preset endpoints, outperformed a comparator vaccine.
  • The company expects the product to support its rabies vaccine portfolio in China, the world’s largest rabies vaccine market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM Vaccine Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260824-12295454), on August 24, 2026, and is solely responsible for the information contained therein.